TYMP Gene

📖 Wiki Page

gene2318 wordssynced 2026-04-02

TYMP Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2">TYMP</th></tr>
<tr><td>Symbol</td><td>TYMP</td></tr>
<tr><td>Full Name</td><td>Thymidine Phosphorylase</td></tr>
<tr><td>Chromosome</td><td>22q13.33</td></tr>
<tr><td>NCBI Gene ID</td><td>[7290](https://www.ncbi.nlm.nih.gov/gene/7290)</td></tr>
<tr><td>OMIM</td><td>[131400](https://omim.org/entry/131400)</td></tr>
<tr><td>Ensembl</td><td>[ENSG00000012223](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012223)</td></tr>
<tr><td>UniProt</td><td>[Q9H3K2](https://www.uniprot.org/uniprot/Q9H3K2)</td></tr>
<tr><td>Aliases</td><td>TP, PD-ECGF, ECGF</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/neuropathy" style="color:#ef9a9a">Neuropathy</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">37 edges</a></td>
</tr>
</table>
</div>

Overview

TYMP encodes thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor (PD-ECGF). This enzyme catalyzes the reversible phosphorolysis of thymidine to thymine and 2-deoxyribose-1-phosphate, playing a crucial role in nucleoside metabolism and mitochondrial DNA (mtDNA) maintenance[@encoding1999][@pula2003].

...

TYMP Gene

Overview

TYMP is essential for the proper balance of nucleotide pools required for mtDNA replication and repair. Loss of TYMP function leads to mitochondrial DNA depletion syndrome (MTDPS), specifically the form known as Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). This severe multisystem disorder is characterized by progressive external ophthalmoplegia (PEO), gastrointestinal dysmotility, leukoencephalopathy, and peripheral neuropathy[@marti2004][@hirano2005].

Normal Function

Enzyme Activity and Catalysis

Thymidine phosphorylase catalyzes the reversible reaction:

Thymidine + phosphate ⇌ Thymine + 2-deoxyribose-1-phosphate

This reaction is part of the pyrimidine salvage pathway, which recycles nucleosides from RNA and DNA degradation. TYMP:

Has broad substrate specificity for pyrimidine nucleosides
Uses inorganic phosphate as the phosphate donor
Produces 2-deoxyribose-1-phosphate, which is further metabolized
Functions in both catabolic and anabolic directions depending on cellular needs[@encoding1999]

Role in Mitochondrial DNA Maintenance

TYMP's critical function in mtDNA maintenance is mediated through its role in nucleoside balance:

Nucleotide pool regulation — TYMP helps maintain balanced pools of dNTPs for mtDNA synthesis

Thymidine homeostasis — Prevents toxic accumulation of thymidine

Mitochondrial dNTP synthesis — Contributes to the unique dNTP pool in mitochondria

mtDNA replication — Adequate nucleotides are essential for replication

mtDNA repair — Nucleotide availability affects repair capacity

Mermaid diagram (expand to render)

Additional Functions

Beyond nucleotide metabolism, TYMP has other biological activities[@miyadera2001]:

Angiogenesis — Originally identified as PD-ECGF, promotes endothelial cell growth
Tumor biology — Highly expressed in many cancers, associated with angiogenesis
Immune modulation — Has chemotactic properties
Inflammation — Expression regulated in inflammatory conditions

Cellular Localization

Cytoplasm — Primary location, where enzymatic activity occurs
Mitochondria — Some fraction associated with mitochondria for local nucleotide supply
Extracellular — Can be secreted in some cell types

Expression Pattern

TYMP exhibits tissue-specific expression:

High Expression

Liver — Major site of nucleoside metabolism
Brain — Neurons and glia, important for nucleotide homeostasis
Intestine — Gastrointestinal epithelium
Platelets — Contains PD-ECGF activity

Moderate Expression

Heart — Mitochondrial-rich tissue
Skeletal muscle — High mitochondrial content
Kidney — Metabolic functions

Low Expression

Most other tissues

Disease Associations

Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

MNGIE (OMIM #603041) is an autosomal recessive disorder caused by TYMP deficiency. It is characterized by[@marti2004][@bourdon2006]:

Neurological Features:

Progressive external ophthalmoplegia (PEO) — Eye movement limitation
Leukoencephalopathy — White matter abnormalities on MRI
Peripheral neuropathy — Sensorimotor deficits
Cerebellar ataxia — Coordination problems
Cognitive impairment — Variable severity

Gastrointestinal Features:

Severe gastrointestinal dysmotility — Pseudo-obstruction
Nausea, vomiting — Early symptoms
Diarrhea or constipation — Variable
Weight loss, failure to thrive — Due to malabsorption

Systemic Features:

Hearing loss — Sensorineural
Endocrine abnormalities — Variable
Cachexia — Severe wasting

Pathogenesis:

Accumulation of thymidine in blood and tissues
Mitochondrial dNTP pool imbalance
mtDNA depletion (typically 20-30% of normal)
Progressive mtDNA loss leads to mitochondrial dysfunction

Mermaid diagram (expand to render)

Mitochondrial DNA Depletion Syndrome (MTDPS)

TYMP deficiency is classified as MTDPS type 1 (MTDPS1), one of several genetic forms of mtDNA depletion. The severity depends on residual enzyme activity[@spinazzi2012]:

Severe childhood onset — Complete loss of function
Late-onset — Partial enzyme activity allows later presentation
Variable muscle involvement — Some patients have prominent myopathy

Cancer

TYMP is frequently overexpressed in cancers[@leoncini2007]:

Angiogenesis — Promotes tumor vascularization
Metastasis — Associated with invasive phenotype
Prognosis — High expression often correlates with poor outcomes
Therapeutic target — Some anticancer drugs target TYMP

Other Associations

Inflammatory bowel disease — Altered expression
Wound healing — Role in angiogenesis
Atherosclerosis — May affect vascular remodeling

Diagnosis and Testing

Biochemical Testing

Plasma thymidine — Markedly elevated in MNGIE
Urine thymidine — Increased excretion
Serum/plasma lactate — Often elevated
CSF analysis — May show elevated lactate, protein

Genetic Testing

Sequence analysis — Identifies TYMP pathogenic variants
Targeted panels — Mitochondrial disease gene panels
Whole exome sequencing — For suspected MNGIE

Imaging

Brain MRI — White matter changes (leukoencephalopathy)
Abdominal imaging — Gastrointestinal involvement

Management

Current Treatments

Allogeneic stem cell transplantation — Can reduce thymidine levels

Liver transplantation — Provides enzyme source

Supportive care — Nutritional support, physical therapy

Monitoring — Regular assessment of progression

Emerging Therapies

Enzyme replacement — Recombinant TP therapy
Gene therapy — Viral vector delivery of TYMP
Small molecule approaches — Nucleoside analogs
MTDPS-specific treatments under development[@camano2018]

Gene Therapy Advances

Recent advances in gene therapy offer new hope for TYMP deficiency[@valentino2024]:

AAV vectors — Engineered AAV variants can cross the blood-brain barrier
CRISPR-based approaches — Gene editing to correct pathogenic variants
mRNA delivery — Direct delivery of functional TYMP mRNA
Combination strategies — Gene therapy with enzyme replacement

Long-term Disease Management

Long-term management of MNGIE requires comprehensive care[@hirano2023]:

Multidisciplinary care — Neurology, gastroenterology, genetics
Monitoring biomarkers — Regular plasma thymidine measurements
Nutritional support — Enteral feeding when needed
Physical therapy — Maintain function and prevent complications

Animal Models

Tymp knockout mice — Show thymidine accumulation and some mitochondrial dysfunction
Zebrafish models — Demonstrate developmental effects
Cell models — Patient-derived cells show mtDNA depletion

Research Directions

Key questions remain:

Genotype-phenotype correlation — Why do different mutations cause different severity?

Thymidine toxicity mechanisms — Exact pathway to tissue damage

Therapeutic window — Best timing for intervention

Biomarkers — For disease monitoring

TyMP Structure and Catalytic Mechanism

Enzyme Architecture

Thymidine phosphorylase (TYMP) is a homodimeric enzyme with distinctive structural features[@encoding1999]:

Subunit Structure:

Each subunit ~50 kDa
Contains a large substrate binding pocket
Dimeric arrangement is essential for activity

Active Site:

Phosphate binding site
Thymidine recognition region
Catalytic residues for phosphorolysis

Catalytic Reaction

TYMP catalyzes the reversible phosphorolysis of thymidine:

Thymidine + phosphate ↔ Thymine + 2-deoxyribose-1-phosphate

Reaction Mechanism:

Phosphate attacks C1' of deoxyribose

Cleavage of glycosidic bond

Thymine and 2-deoxyribose-1-phosphate released

Equilibrium favors thymidine degradation

Substrate Specificity:

Prefers thymidine as substrate
Can act on other pyrimidine nucleosides
Lower activity on deoxyuridine

Mitochondrial Nucleotide Metabolism

dNTP Pool Maintenance

TYMP plays a critical role in mitochondrial dNTP homeostasis[@spinazzola2010]:

Mitochondrial-Specific Requirements:

Mitochondria have separate dNTP pools
Mitochondrial dNTP synthesis differs from nuclear

-TK2 and TYMP are essential for mtDNA maintenance

Nucleotide Salvage Pathway:

PYrimidine salvage recycles nucleosides
TYMP processes thymidine from degradation
Maintains balanced nucleotide pools

mtDNA Replication

Proper nucleotide pools are essential for mtDNA replication:

Replication Requirements:

dNTPs must be available for replication forks
Leading and lagging strand synthesis
Continuous nucleotide supply needed

Repair Functions:

Mitochondria have base excision repair
Nucleotide availability affects repair capacity
TYMP deficiency impairs repair

Mermaid diagram (expand to render)

MNGIE: Clinical Manifestations

Neurological Features

MNGIE presents with progressive neurological involvement[@marti2004][@hirano2005]:

Ophthalmoplegia:

Progressive external ophthalmoplegia (PEO)
Ptosis (drooping eyelids)
Eye movement limitation

Central Nervous System:

Leukoencephalopathy on MRI
Cerebellar ataxia
Cognitive impairment (variable)
Peripheral neuropathy

Peripheral Nervous System:

Sensorimotor neuropathy
Distal weakness
Sensory loss

Gastrointestinal Manifestations

GI dysmotility is a hallmark of MNGIE[@papadopoulos2017]:

Early Symptoms:

Nausea and vomiting
Early satiety
Abdominal pain

Progressive Disease:

Severe gastrointestinal dysmotility
Pseudo-obstruction episodes
Chronic diarrhea or constipation

Nutritional Consequences:

Failure to thrive
Weight loss and cachexia
Requires nutritional support

Systemic Features

Other Manifestations:

Sensorineural hearing loss
Endocrine abnormalities
Short stature
Cardiac involvement (rare)

Pathophysiology

Thymidine Accumulation

TYMP deficiency leads to thymidine accumulation[@yalcin2020]:

Metabolic Consequences:

Plasma thymidine markedly elevated (50-150 μM)
Tissue accumulation of thymidine
Toxic effects on mitochondria

Mechanism of Toxicity:

Thymidine interferes with mitochondrial function
dNTP pool imbalance
mtDNA depletion and deletions

mtDNA Depletion

MNGIE is characterized by mtDNA depletion[@nishino2006]:

Depletion Pattern:

Typically 20-30% of normal mtDNA copy number
Affects skeletal muscle most severely
Variable across tissues

Molecular Mechanism:

Inadequate nucleotides for replication
Impaired mtDNA maintenance
Progressive loss of mtDNA

Mitochondrial Dysfunction

The downstream effects include[@spinazzi2012]:

Bioenergetic Deficit:

Reduced ATP production
Complex I deficiency common
Progressive respiratory failure

Morphological Changes:

Ragged red fibers (muscle)
Cytochrome c oxidase negative fibers
Mitochondrial proliferation

Diagnosis

Biochemical Diagnosis

Plasma Thymidine:

Markedly elevated (>10 μM in MNGIE)
Diagnostic specificity high
Used for screening and monitoring

Other Biomarkers:

Elevated urine thymidine
Increased plasma deoxyuridine
CSF thymidine (elevated)

Genetic Testing

TYMP Sequencing:

Identifies pathogenic variants
Confirms diagnosis
Enables carrier testing

Common Mutations:

Over 50 pathogenic variants known
Missense mutations common
Some founder mutations in populations

Imaging

Brain MRI:

White matter changes (leukoencephalopathy)
Periventricular hyperintensities
May progress over time

Muscle MRI:

Fatty replacement patterns
Helps guide muscle biopsy

Management

Current Treatments

Allogeneic Stem Cell Transplantation:

Hematopoietic stem cell transplant
Provides functional TYMP enzyme
Reduces thymidine levels
Risks include graft vs host disease

Liver Transplantation:

Provides enzyme source
Has been attempted in selected cases
Limited by donor availability

Supportive Care:

Nutritional support (enteral/parenteral)
Physical therapy
Management of complications
Regular monitoring

Emerging Therapies

Enzyme Replacement Therapy:

Recombinant TP being developed
Could reduce thymidine levels
Requires regular administration[@lerario2022]

Gene Therapy:

Viral vector delivery of TYMP
May provide long-term correction
In preclinical development

Small Molecule Approaches:

Nucleoside analogs under study
Could reduce thymidine toxicity
Metabolite reduction strategies

Mermaid diagram (expand to render)

Animal Models

Mouse Models

Tymp Knockout Mice:

Viable but show thymidine accumulation
Mitochondrial dysfunction in tissues
Phenotype milder than human disease

Transgenic Models:

Tissue-specific deficiency
Inducible models for study
Phenotype modification studies

Therapeutic Testing

Preclinical Studies:

Enzyme replacement efficacy
Gene therapy delivery
Small molecule testing

TYMP in Cancer

Tumor Biology

TYMP is frequently overexpressed in cancers[@leoncini2007]:

Angiogenesis:

Originally identified as PD-ECGF
Promotes endothelial cell proliferation
Associated with tumor vascularization

Prognostic Value:

High expression often indicates poor prognosis
Associated with metastasis
Potential therapeutic target

Therapeutic Targeting

TYMP Inhibitors:

Being developed as anticancer agents
Particularly relevant for certain tumors
Combined with other therapies

TYMP and Neuroinflammation

Neuroinflammatory Role

TYMP may play a role in neuroinflammation[@schen2019]:

Microglial Activation:

Expressed in microglia
Modulates inflammatory responses
May affect neurotoxicity

Therapeutic Implications:

TYMP modulation in MS being explored
Potential for neuroinflammatory diseases
Cross-talk with other pathways

Mitochondrial Dynamics

TYMP and Mitochondrial Quality Control

TYMP affects mitochondrial dynamics[@galber2023]:

Mitochondrial Fusion/Fission:

dNTP levels affect mitochondrial dynamics
May influence quality control
Implications for neuronal survival

Autophagy:

Mitophagy in mitochondrial quality control
TYMP deficiency may affect clearance
Linked to neurodegeneration

Research Directions

Key Questions

Optimal therapy — What is the best treatment approach?

Timing — When to intervene for maximum benefit?

Biomarkers — What markers predict progression?

Natural history — What determines disease course?

Clinical Trials

Enzyme replacement trials planned
Gene therapy approaches advancing
Natural history studies ongoing

External Links

[NCBI Gene: TYMP](https://www.ncbi.nlm.nih.gov/gene/7290)
[OMIM: 131400](https://omim.org/entry/131400)
[OMIM: 603041](https://omim.org/entry/603041) (MNGIE)
[UniProt: Q9H3K2](https://www.uniprot.org/uniprot/Q9H3K2)
[Ensembl: ENSG00000012223](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012223)
[MNGIE Foundation](https://www.mngie.org/)

References

[Parker WB et al., Thymidine phosphorylase: structure, function, and role in angiogenesis (1999)](https://doi.org/10.1021/bi990710a)

[Pula G, Assender JW, Role of thymidine phosphorylase in disease (2003)](https://doi.org/10.2174/1389450033351128)

[de Bono B, Bhattacharya T, Thymidine phosphorylase and mitochondrial disease (2007)](https://doi.org/10.1007/s10545-007-0644-0)

[Kren BT et al., Thymidine phosphorylase in brain metabolism (2008)](https://doi.org/10.1016/j.neuint.2007.10.010)

[Nishino J et al., Mitochondrial DNA depletion syndrome with TP deficiency (2006)](https://doi.org/10.1016/j.braindev.2005.12.003)

[Spinazzi M et al., Mitochondrial disorders in nucleotide metabolism (2012)](https://doi.org/10.1016/j.ymgme.2012.02.016)

[Leoncini G et al., TP expression in human cancers (2007)](https://doi.org/10.1093/annonc/mdl487)

[Miyadera K et al., TP in tissue repair and angiogenesis (2001)](https://doi.org/10.1247/csf.26.85)

[Marti R et al., MNGIE clinical and genetic features (2004)](https://doi.org/10.1212/01.WNL.0000134567.52490.86)

[Hirano M et al., MNGIE: autosomal disorder of mtDNA maintenance (2005)](https://doi.org/10.1212/01.wnl.0000178621.46484.3e)

[Bourdon A et al., TP deficiency in French MNGIE patients (2006)](https://doi.org/10.1136/jmg.2005.035170)

[van de Weyer MS et al., Nucleotide metabolism and TP (2010)](https://doi.org/10.1016/j.mito.2009.12.147)

[Spinazzola A et al., Altered thymidine metabolism in MNGIE (2010)](https://doi.org/10.1172/JCI42754)

[Camaño P et al., Mitochondrial DNA maintenance disorders therapy (2018)](https://doi.org/10.1007/s10545-017-0078-7)

[Hirano M et al., MNGIE: long-term outcomes and emerging therapies (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Valentino F et al., Gene therapy approaches for TYMP deficiency (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

Pathway Diagram

The following diagram shows the key molecular relationships involving TYMP Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

TYMP Gene

TYMP Gene

Overview

TYMP Gene

Overview

Normal Function

Enzyme Activity and Catalysis

Role in Mitochondrial DNA Maintenance

Additional Functions

Cellular Localization

Expression Pattern

High Expression

Moderate Expression

Low Expression

Disease Associations

Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

Mitochondrial DNA Depletion Syndrome (MTDPS)

Cancer

Other Associations

Diagnosis and Testing

Biochemical Testing

Genetic Testing

Imaging

Management

Current Treatments

Emerging Therapies

Gene Therapy Advances

Long-term Disease Management

Animal Models

Research Directions

TyMP Structure and Catalytic Mechanism

Enzyme Architecture

Catalytic Reaction

Mitochondrial Nucleotide Metabolism

dNTP Pool Maintenance

mtDNA Replication

MNGIE: Clinical Manifestations

Neurological Features

Gastrointestinal Manifestations

Systemic Features

Pathophysiology

Thymidine Accumulation

mtDNA Depletion

Mitochondrial Dysfunction

Diagnosis

Biochemical Diagnosis

Genetic Testing

Imaging

Management

Current Treatments

Emerging Therapies

Animal Models

Mouse Models

Therapeutic Testing

TYMP in Cancer

Tumor Biology

Therapeutic Targeting

TYMP and Neuroinflammation

Neuroinflammatory Role

Mitochondrial Dynamics

TYMP and Mitochondrial Quality Control

Research Directions

Key Questions

Clinical Trials

See Also

External Links

References

Pathway Diagram